Search Results - "Cox, Kerry L."

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy by Lim, Sean H., Vaughan, Andrew T., Ashton-Key, Margaret, Williams, Emily L., Dixon, Sandra V., Chan, H. T. Claude, Beers, Stephen A., French, Ruth R., Cox, Kerry L., Davies, Andrew J., Potter, Kathleen N., Mockridge, C. Ian, Oscier, David G., Johnson, Peter W.M., Cragg, Mark S., Glennie, Martin J.

“…The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that…”
Get full text

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo by Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M., Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn, Cragg, Mark S.

“…Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and…”
Get full text

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection by Beers, Stephen A., French, Ruth R., Chan, H.T. Claude, Lim, Sean H., Jarrett, Timothy C., Vidal, Regina Mora, Wijayaweera, Sahan S., Dixon, Sandra V., Kim, Hyungjin, Cox, Kerry L., Kerr, Jonathan P., Johnston, David A., Johnson, Peter W.M., Verbeek, J. Sjef, Glennie, Martin J., Cragg, Mark S.

“…Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this…”
Get full text

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations by Willoughby, Jane E, Dou, Lang, Bhattacharya, Sabyasachi, Jackson, Heather, Seestaller-Wehr, Laura, Kilian, David, Bover, Laura, Voo, Kui S, Cox, Kerry L, Murray, Tom, John, Mel, Shi, Hong, Bojczuk, Paul, Jing, Junping, Niederer, Heather, Shepherd, Andrew J, Hook, Laura, Hopley, Stephanie, Inzhelevskaya, Tatyana, Penfold, Chris A, Mockridge, C Ian, English, Vikki, Brett, Sara J, Srinivasan, Roopa, Hopson, Christopher, Smothers, James, Hoos, Axel, Paul, Elaine, Martin, Stephen L, Morley, Peter J, Yanamandra, Niranjan, Cragg, Mark S

“…BackgroundOX40 has been widely studied as a target for immunotherapy with agonist antibodies taken forward into clinical trials for cancer where they are yet…”
Get full text

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion by Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S

“…BackgroundImmune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic…”
Get full text

Domain binding and isotype dictate the activity of anti-human OX40 antibodies by Griffiths, Jordana, Hussain, Khiyam, Smith, Hannah L, Sanders, Theodore, Cox, Kerry L, Semmrich, Monika, Mårtensson, Linda, Kim, Jinny, Inzhelevskaya, Tatyana, Penfold, Chris A, Tutt, Alison L, Mockridge, C Ian, Chan, HT Claude, English, Vikki, French, Ruth F, Teige, Ingrid, Al-Shamkhani, Aymen, Glennie, Martin J, Frendeus, Bjorn L, Willoughby, Jane E, Cragg, Mark S

“…BackgroundPrevious data suggests that anti-OX40 mAb can elicit anti-tumor effects in mice through deletion of Tregs. However, OX40 also has powerful…”
Get full text

Reducing affinity as a strategy to boost immunomodulatory antibody agonism by Yu, Xiaojie, Orr, Christian M., Chan, H. T. Claude, James, Sonya, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Essex, Jonathan W., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.

“…Antibody responses during infection and vaccination typically undergo affinity maturation to achieve high-affinity binding for efficient neutralization of…”
Get full text

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy by Dahal, Lekh N, Dou, Lang, Hussain, Khiyam, Liu, Rena, Earley, Alexander, Cox, Kerry L, Murinello, Salome, Tracy, Ian, Forconi, Francesco, Steele, Andrew J, Duriez, Patrick J, Gomez-Nicola, Diego, Teeling, Jessica L, Glennie, Martin J, Cragg, Mark S, Beers, Stephen A

“…Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis, and metastasis. Macrophages are also the key effector cell for mAb…”
Get full text

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance by Mellone, Massimiliano, Piotrowska, Klaudia, Venturi, Giulia, James, Lija, Bzura, Aleksandra, Lopez, Maria A, James, Sonya, Wang, Chuan, Ellis, Matthew J, Hanley, Christopher J, Buckingham, Josephine F, Cox, Kerry L, Hughes, Gareth, Valge-Archer, Viia, King, Emma V, Beers, Stephen A, Jaquet, Vincent, Jones, George D D, Savelyeva, Natalia, Sayan, Emre, Parsons, Jason L, Durant, Stephen, Thomas, Gareth J

“…Myofibroblastic cancer-associated fibroblast (myoCAF)-rich tumors generally contain few T cells and respond poorly to immune-checkpoint blockade. Although…”
Get full text

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies by Tipton, Thomas R.W., Roghanian, Ali, Oldham, Robert J., Carter, Matthew J., Cox, Kerry L., Mockridge, C. Ian, French, Ruth R., Dahal, Lekh N., Duriez, Patrick J., Hargreaves, Philip G., Cragg, Mark S., Beers, Stephen A.

“…Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has…”
Get full text

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment by Turaj, Anna H., Hussain, Khiyam, Cox, Kerry L., Rose-Zerilli, Matthew J.J., Testa, James, Dahal, Lekh N., Chan, H.T. Claude, James, Sonya, Field, Vikki L., Carter, Matthew J., Kim, Hyung J., West, Jonathan J., Thomas, Lawrence J., He, Li-Zhen, Keler, Tibor, Johnson, Peter W.M., Al-Shamkhani, Aymen, Thirdborough, Stephen M., Beers, Stephen A., Cragg, Mark S., Glennie, Martin J., Lim, Sean H.

“…Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic…”
Get full text

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells by Ivanov, Andrei, Beers, Stephen A, Walshe, Claire A, Honeychurch, Jamie, Alduaij, Waleed, Cox, Kerry L, Potter, Kathleen N, Murray, Stephen, Chan, Claude H T, Klymenko, Tetyana, Erenpreisa, Jekaterina, Glennie, Martin J, Illidge, Tim M, Cragg, Mark S

“…mAbs are becoming increasingly utilized in the treatment of lymphoid disorders. Although Fc-FcgammaR interactions are thought to account for much of their…”
Get full text

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking by Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.

“…CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells…”
Get full text

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms by Simpson, Alexander P., Roghanian, Ali, Oldham, Robert J., Chan, H.T. Claude, Penfold, Christine A., Kim, Hyung J., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Bogdanov, Yury D., James, Sonya, Tutt, Alison L., Rycroft, Daniel, Morley, Peter, Dahal, Lekh N., Teige, Ingrid, Frendeus, Björn, Beers, Stephen A., Cragg, Mark S.

“…Many therapeutic antibodies deplete target cells and elicit immunotherapy by engaging activating Fc gamma receptors (FcγRs) on host effector cells. These…”
Get full text

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo by Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R, Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J, Marshall, Michael J E, Cox, Kerry L, Turaj, Anna H, Cragg, Mark S, Klein, Christian, Carter, Matthew J, Tannheimer, Stacey

“…Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with…”
Get full text

Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures by Johnston, Harvey E., Carter, Matthew J., Cox, Kerry L., Dunscombe, Melanie, Manousopoulou, Antigoni, Townsend, Paul A., Garbis, Spiros D., Cragg, Mark S.

“…Approximately 800,000 leukemia and lymphoma cases are diagnosed worldwide each year. Burkitt's lymphoma (BL) and chronic lymphocytic leukemia (CLL) are…”
Get full text

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors by Tutt, Alison L, James, Sonya, Laversin, Stéphanie A, Tipton, Thomas R W, Ashton-Key, Margaret, French, Ruth R, Hussain, Khiyam, Vaughan, Andrew T, Dou, Lang, Earley, Alexander, Dahal, Lekh N, Lu, Chen, Dunscombe, Melanie, Chan, H T Claude, Penfold, Christine A, Kim, Jinny H, Potter, Elizabeth A, Mockridge, C Ian, Roghanian, Ali, Oldham, Robert J, Cox, Kerry L, Lim, Sean H, Teige, Ingrid, Frendéus, Bjorn, Glennie, Martin J, Beers, Stephen A, Cragg, Mark S

“…FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through…”
Get full text

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression by Cummin, ThomasE.C., Cox, Kerry L., Murray, Tom D., Turaj, Anna H., Dunning, Lisa, English, Vikki L., Fell, Rachel, Packham, Graham, Ma, Yan, Powell, Ben, Johnson, PeterW.M., Cragg, Mark S., Carter, Matthew J.

“…Although the MYC oncogenic network represents an attractive therapeutic target for lymphoma, MYC inhibitors have been difficult to develop. Alternatively,…”
Get full text

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization by Williams, Emily L, Tutt, Alison L, Beers, Stephen A, French, Ruth R, Chan, Claude H T, Cox, Kerry L, Roghanian, Ali, Penfold, Christine A, Butts, Cherié L, Boross, Peter, Verbeek, J Sjef, Cragg, Mark S, Glennie, Martin J

“…Genetic deficiency of the inhibitory Fc receptor, FcγRIIB (CD32b), has been shown to augment the activity of activatory FcγR and promote mAb immunotherapy. To…”
Get full text

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B) by Williams, Emily L., Tutt, Alison L., French, Ruth R., Chan, H. T. Claude, Lau, Betty, Penfold, Christine A., Mockridge, C. Ian, Roghanian, Ali, Cox, Kerry L., Verbeek, J. Sjef, Glennie, Martin J., Cragg, Mark S.

“…Fc receptors (FcRs) play a key role in regulating and coordinating responses from both innate and adaptive arms of the immune system. The inhibitory Fc gamma…”
Get full text